Active, not recruitingInterventional · Phase 2NCT03505320 ↗A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
RecruitingInterventional · Phase 2NCT03899155 ↗Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer TherapiesAna M. MolinaPIInterventionDrug: Nivolumab · Drug: Ipilimumab · Drug: Cabozantinib · Drug: Trametinib · Drug: Relatlimab · Drug: Nivolumab + Relatlimab · Drug: Capecitabine · Drug: Bevacizumab · Drug: Temozolomide · Drug: Rucaparib · Drug: Daratumumab · Drug: Regorafinib · Drug: Leucovorin · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Enzalutamide · Drug: Sunitinib · Drug: Pemetrexed · Drug: PembrolizumabDatesAug 2019 – Aug 2029 (est.)SponsorBristol-Myers Squibb CompanyCancer
Active, not recruitingInterventional · Phase 2NCT04486378 ↗A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following ResectionManish A ShahPIInterventionDrug: RO7198457 intravenous (IV) · Other: Observational group (no intervention)DatesMar 2021 – Nov 2026 (est.)SponsorBioNTech SEColorectal Cancer Stage IIColorectal Cancer Stage III
Active, not recruitingInterventional · Phase 2NCT05482971 ↗A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential ThrombocythemiaGhaith Abu-ZeinahPIInterventionDrug: Ropeginterferon alfa-2b-njft (P1101)DatesSep 2022 – May 2025SponsorPharmaEssentiaEssential Thrombocythemia
RecruitingInterventional · Phase 2NCT06623656 ↗Multicenter Randomized Phase II Trial of Neoadjuvant Radioimmunotherapy Versus Chemoimmunotherapy in Patients With Clinical Stages IB-III (N2) Non-small Cell Lung CancerNasser K AltorkiPIInterventionDrug: Cemiplimab · Drug: Platinum based chemotherapy · Radiation: Stereotactic body radiation therapyDatesFeb 2025 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityCarcinoma, Non-Small-Cell Lung
RecruitingInterventional · Phase 2NCT07216443 ↗A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeAlexandra Gomez ArteagaPIInterventionBiological: Orca-TDatesDec 2025 – Nov 2027 (est.)SponsorOrca BiosystemsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
CompletedInterventional · Phase 2NCT03822351 ↗A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)Ashish SaxenaPIInterventionDrug: Durvalumab + Oleclumab · Drug: Durvalumab · Drug: Durvalumab + MonalizumabDatesDec 2018 – Jul 2023· Results postedSponsorMedImmune, LLCStage III Non-small Cell Lung CancerUnresectable
CompletedInterventional · Phase 2NCT03915951 ↗A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerAshish SaxenaPIInterventionDrug: encorafenib · Drug: binimetinibDatesJun 2019 – Sep 2022· Results postedSponsorArray BioPharma Inc.Non-small Cell Lung Cancer
CompletedInterventional · Phase 2NCT05673811 ↗A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerAlana NguyenPIInterventionDrug: Nab-paclitaxel · Drug: Gemcitabine · Genetic: VCN-01DatesJan 2023 – Mar 2025· Results postedSponsorTheriva Biologics, Inc.Pancreatic AdenocarcinomaMetastatic